Purpose The majority of breast cancer patients receive endocrine therapy, including aromatase inhibitors known to cause increased bone resorption. Bone-related biomarkers at the time of breast cancer diagnosis may predict future risk of osteoporosis and fracture after endocrine therapy. Methods In a large population of 2,401 female breast cancer patients who later underwent endocrine therapy, we measured two bone remodeling biomarkers, TRAP5b and BAP, and two bone regulating biomarkers, RANKL and OPG, in serum samples collected at the time of breast cancer diagnosis. We analyzed these biomarkers and their ratios with patients' demographic, lifestyle, clinical tumor characteristics, as well as bone health history. Results The presence of bone metastases, prior bisphosphonate (BP) treatment, and blood collection after chemotherapy had a significant impact on biomarker levels. After excluding these cases and controlling for blood collection time, several factors, including age, race/ethnicity, body mass index, physical activity, alcohol consumption, smoking, and hormonal replacement therapy, were significantly associated with bone biomarkers, while vitamin D or calcium supplements and tumor characteristics were not. When prior BP users were included in, recent history of osteoporosis and fracture was also associated. Conclusions Our findings support further investigation of these biomarkers with bone health outcomes after endocrine therapy initiation in women with breast cancer.
Introduction
Despite its rigid appearance, bone is metabolically active and undergoes constant remodeling. The counteracting processes of bone formation and resorption reflect the activities of two types of osteocytes, osteoblasts, and osteoclasts, both of which are regulated by a central signaling axis consisting of three molecules: receptor activator of nuclear factor kappa-B (RANK), RANK ligand (RANKL), and osteoprotegerin (OPG) [1] . RANKL produced by osteoblasts binds to RANK, the receptor expressed on the surface of osteoclasts and essential for the differentiation and maturation of osteoclasts, thus favoring bone resorption. OPG, also produced by osteoblasts, is a decoy receptor for RANKL, and its binding by RANKL blocks osteoclast formation and suppresses bone resorption.
When bone resorption is more active, it leads to a loss of bone mass and weakened bone microarchitecture, predisposing patients to osteoporotic fractures. While bone mineral density (BMD) measured by dual energy X-ray absorptiometry (DXA) remains the standard for diagnosis of osteoporosis [2] , biochemical markers of bone resorption and formation may also be useful as adjunctive measures for predicting future bone loss and bone fragility [3] .
In recent years, a number of bone biomarkers have been studied with BMD, osteoporosis, or fractures [4] . A selective combination of formation and resorption biomarkers in blood or urine samples are usually measured in parallel; yet bone regulating markers, including RANKL and OPG, have only been occasionally examined [4] . Furthermore, these studies were conducted largely in noncancer populations, except for women diagnosed with breast cancer where several studies have examined bone remodeling biomarkers before and after endocrine therapy, including tamoxifen and aromatase inhibitors (AIs) [5] [6] [7] [8] . However, to our knowledge, no previous studies have examined bone biomarkers with patients' demographic, lifestyle, or tumor characteristics at the time of breast cancer diagnosis. A better understanding of bone biomarkers and their relationships with other clinical characteristics at baseline and with prior history of bone health may be particularly relevant to patients treated with AIs, for predicting future bone health outcomes. Because it has been hypothesized that women diagnosed with breast cancer are likely to have higher BMD than those without breast cancer due to stronger estrogen exposures [9] [10] [11] , it would be important to characterize these relationships which may differ from those in non-cancer populations.
The present study addresses current research gaps using data from a large contemporary breast cancer survivor cohort. Serum samples collected soon after cancer diagnosis were used for measuring the levels of bone biomarkers. In addition to RANKL and OPG, the two central bone regulating molecules indicative of osteocyte activity, we also selected two bone remodeling biomarkers, tartrate-resistant acid phosphatase (TRAP5b), an osteoclastic enzyme for bone resorption, and bone alkaline phosphatase (BAP), an osteoblastic enzyme for bone formation. Both BAP and TRAP5b have been commonly used in bone metabolism studies, given their relatively low intra-individual variability, low circadian variability, and high thermostability [4] . We examined the relationship of these biomarkers with patient characteristics and prior bone health history at the time of breast cancer diagnosis.
Methods

Patient population
The study population was drawn from the Pathways Study, a prospective cohort study of breast cancer survivors at Kaiser Permanente Northern California (KPNC). Details of the study have been published elsewhere [12] . In brief, a total of 4505 eligible patients were identified through rapid case ascertainment procedures and enrolled in the study from January 2006 to April 2013 by completion of a baseline in-person interview. Women were enrolled on average two months post-diagnosis. Extensive information on sociodemographic and lifestyle factors established breast cancer risk factors, and health and medical history was collected by interviewer-and self-administered questionnaires at baseline. Anthropometric measures were also obtained at baseline. Blood samples were obtained after the baseline interview from 90% of participants. Non-fasting blood was drawn by phlebotomy and shipped on dry ice overnight to Roswell Park Cancer Institute (RPCI) for processing through the auspices of the Data Bank and Biorepository (DBBR) [13] . Red blood cells, buffy coat, plasma, and sera were aliquoted into 0.5 ml straws using the MAPI Cryobiosystem (IMV Tech., Paris, France), slow frozen to -80°C, and transferred to liquid nitrogen for long-term storage until analysis.
A total of 3315 Pathways Study participants treated with tamoxifen or aromatase inhibitor (AI) were included in an ancillary study to investigate lifestyle, molecular, and genetic factors for bone health among breast cancer patients [14] . For the measurement of bone biomarkers, patients who had blood samples collected and were treated with either tamoxifen or AI but not both were included (n = 2401).
Measurement of bone biomarkers in serum samples
The four bone biomarkers were measured using serum samples collected at a median time of 73 days after breast cancer diagnosis (range: 28-321 days). ELISA assays for each biomarker were performed using the following commercially available kits: TRAP5b and BAP from Quidel (San Diego, CA), OPG from R&D System (Minneapolis, MN), and total soluble RANKL from Biovendor (Asheville, NC). All assays were performed according to manufacturers' protocols and each sample tested in duplicates, and those with a coefficient of variation (CV) exceeding 15% were repeated. The average CV was 2.3% for TRAP5b assay, 1.9% for BAP assay, 5.8% for RANKL assay, and 5.5% for OPG assay.
Collection of clinical data, bone mineral density, and patient history of osteoporosis and fracture Breast tumor characteristics were obtained from the KPNC Cancer Registry approximately 6-month post-diagnosis. Bone mineral density data were obtained from women who underwent DXA at KPNC medical facilities using a Hologic densitometer, the near exclusive type of scanner used at KPNC except for central California medical centers which did not include Pathways participants. A small proportion of scans done using a GE Lunar densitometer were excluded from the BMD analysis. Algorithms were developed to extract BMD values for the femoral neck, total hip, and lumbar spine from the radiology reports of DXA scans in the KPNC electronic medical record (EMR) using key text string searches. The performance of the algorithm was validated by manual review of a random subset of patients (n = 239 with 532 BMD values) and comparison to electronic data obtained directly from Hologic machines prior to 2008 [15] , which showed a 96.2% concordance rate. Baseline BMD at the time of breast cancer diagnosis was determined from DXA scans obtained within 3 years prior or within 1 year after the breast cancer diagnosis; for patients with multiple DXA scans within this time interval, the one closest to the time of breast cancer diagnosis was used. T-scores were calculated from BMD values for osteoporosis classification, using the following formula: T-score = (observed BMD -peak BMD)/standard deviation of peak BMD, with peak BMD values obtained from Hologic (for lumbar spine) or Hologic NHANES III (for femoral neck or total hip) Caucasian reference populations. For these analyses, we used calculated T-scores rather than those provided in the report due to challenges with T-score extraction using key text string searches. Osteoporosis was defined by a BMD T-score of -2.5 or below, osteopenia by BMD T-score between -1 and -2.5, and normal BMD [16] by T-score of -1 or greater [17] . History of diagnosed osteoporosis and fracture before breast cancer diagnosis was identified based on appropriate ICD-9 codes [14] and prescription data of bisphosphonate (BP) use from the KPNC EMR and categorized based on years before cancer diagnosis (\5 years and C5 years). Traumatic and pathologic fractures were excluded. In addition to any clinical fracture, major osteoporotic fracture was defined as those to the spine, hip, humerus, and wrist.
Statistical analysis
Descriptive characteristics of the patient population were summarized using mean and standard deviation for continuous variables and count and percentage for categorical variables. Distributions of the biomarker levels were examined, and no evidence of deviation from a normal distribution was found. The ratios of BAP/TRAP5b and OPG/RANKL were log-transformed to improve distribution normality. Correlations between bone biomarker levels and BMD and T-scores were assessed using Pearson correlation test.
Associations of bone biomarker levels with factors that might markedly affect these levels were first tested using a generalized linear model, controlling for age at diagnosis and menopausal status. These factors included bone metastasis, prior BP treatment, time of blood collection relative to chemotherapy initiation, and time of blood collection relative to endocrine therapy initiation. Least squared means and corresponding confidence intervals of bone biomarkers for each factor assessed are presented. Because our analyses demonstrated a significant impact on biomarker levels from bone metastasis, prior BP treatment and timing of blood collection after chemotherapy infusion, we excluded the small number of patients with bone metastasis (n = 20) and prior BP treatment (n = 200) from subsequent analyses examining the association with demographic, lifestyle, and clinical factors. However, because BP treatment was an indication of osteoporosis, when analyzing prior bone health history, we included the prior BP users. Additional analyses were also performed after excluding them. We also controlled for time of blood collection relative to chemotherapy [mean (SD) = 8 (96) days] in multivariable linear models. Sensitivity analyses were also performed by excluding patients with blood collected after the chemotherapy initiation (n = 554).
Associations of bone biomarker levels with cancer clinical characteristics and bone health history were tested using the same generalized linear model approach described above. In addition to the four measured biomarkers, we also assessed the ratios of bone formation and resorption markers, BAP/TRAP5b, and OPG/RANKL. All analyses were also stratified by menopausal status at the time of breast cancer diagnosis. The Bonferroni method was applied to correct for study-wide multiple comparison errors (6 markers times 20 variables).
Results
Descriptive characteristics of the patient population
A total of 2401 breast cancer patients were included in the biomarker analysis. Table 1 summarizes the demographic, lifestyle, and clinical characteristics, as well as bone health history before breast cancer diagnosis of the patient population, overall, and by menopausal status. The average age at diagnosis was 60.4 years, with a majority diagnosed after menopause (n = 1775, or 74%). The majority of patients were white (67%), overweight (31%), or obese (36%), engaged in some physical activity (96%), never smoked (56%), drank alcohol (73%), did not use supplements (64%), previously used birth control (75%) and, among postmenopausal women, took hormone replacement therapy (59%). Most patients were diagnosed with earlystage breast cancer, with 29 stage IV cancer patients, including 20 patients with metastatic disease to the bone. As expected, almost all patients had hormone receptor positive tumors; however, 4 patients had HER2-enriched tumors (ER-, PR-and HER2?) and 7 had triple-negative tumors (ER-, PR-, and HER2-), which were subsequently confirmed by chart review. Only 7% of patients had a history of osteoporosis prior to breast cancer diagnosis, while 13% had a prior history of any fracture and 4% had a prior history of any major fracture. Most of the prior osteoporosis or fracture diagnoses occurred among postmenopausal women, and the first fracture occurred at or after age 55 years.
Impact of bone metastasis, prior bisphosphonate treatment, and time of blood collection on the measured biomarker levels
As shown in Supplementary Table 1, 20 patients with bone metastasis had much higher levels of BAP and TRAP5b levels than those with non-bone metastasis or no metastasis. Patients previously treated with BP (n = 200, 8%) had lower levels of BAP and TRAP5b levels than those who did not, but there was no difference in the levels of RANKL or OPG. Although blood collection after endocrine therapy initiation (n = 1695, 71%) had no impact on any of the measured biomarker levels, samples collected after chemotherapy initiation (n = 554, 23%) had higher levels of TRAP5b and lower levels of RANKL compared to samples collected prior to chemotherapy or from patients not treated with chemotherapy.
Correlations between bone biomarkers and BMD
After excluding patients with bone metastasis and prior BP treatment, we examined correlations between BMD (spine, hip, and femur) at time close to breast cancer diagnosis (within 3 years prior and 1 year post) and levels of the four biomarkers, as well as BAP/TRAP5b and OPG/RANKL ratios. The median time interval between DXA scan and blood draw was -63 days (range: -1188 to 260 days). As shown in Supplementary Table 2, among the four biomarkers, the only correlation was between TRAP5b and BAP (r = 0.37, p \ 0.001), while RANKL and OPG were not correlated (r = -0.01). Supplementary Table 2 also displays the correlations between biomarker levels and BMD and T-scores. Both TRAP5b and BAP were negatively correlated with BMD at hip and femur, with the strongest correlation between TRAP5b and femur BMD (r = -0.22, p \ 0.001). RANKL and OPG levels were not correlated with BMD, except for a weak correlation between OPG level and the OPG/RANKL ratio with spine BMD.
Associations of bone biomarker levels with demographic and lifestyle factors
A number of demographic and lifestyle factors were associated with bone remodeling biomarkers ( Table 2) and bone regulating biomarkers (Table 3) . Patients diagnosed at an older age had higher levels of TRAP5b, lower BAP/ TRAP5b ratio, lower levels of RANKL, higher levels of OPG, and higher OPG/RANKL ratio (p \ 0.001). Black women had the highest levels of TRAP5b and OPG and OPG/RANKL ratio (p \ 0.001). Women with a higher body mass index had lower levels of TRAP5b, higher levels of BAP, and thus higher BAP/TRAP5b ratio; lower levels of RANKL, higher levels of OPG, and thus higher OPG/RANKL ratio (p B 0.007). Higher physical activity was associated with higher levels of TRAP5b, lower BAP/ TRAP5b ratio, and lower levels of OPG (p B 0.001).
Higher alcohol intake was associated with lower levels of BAP, lower BAP/TRAP5b ratio, lower levels of OPG, and lower OPG/RANKL ratio (p B 0.003). In addition, current smoking and hormone replacement therapy use were associated with higher and lower levels of OPG, respectively, but not with the other biomarkers measured. Supplement use (either calcium, vitamin D, or both) or birth control use had little impact on bone biomarker levels. The results remained unchanged after stratifying by menopausal status at the time of breast cancer diagnosis, or excluding samples collected after the chemotherapy initiation (data not shown).
Associations of bone biomarker levels with tumor characteristics
Overall, we did not observe strong associations of bone biomarker levels with tumor characteristics (Tables 4, 5 ). The only two exceptions were higher TRAP5b levels in PR negative than in PR positive patients (p \ 0.001), and patients with higher grade tumors had higher levels of BAP (p = 0.02). The results remained unchanged after stratifying by menopausal status at the time of breast cancer diagnosis, or excluding samples collected after chemotherapy initiation (data not shown).
Associations of bone biomarker levels with history of osteoporosis and fracture
Patients with a history of osteoporosis (including those with prior BP use), particularly those with a more recent history within 5 years before breast cancer diagnosis, had lower levels of TRAP5b, BAP, and RANKL (Tables 4, 5) . Similarly, those with a recent history of any fracture also had lower levels of TRAP5b and BAP, although the difference in BAP was not statistically significant. The results were similar after excluding samples collected after chemotherapy initiation (data not shown). Upon stratification by menopausal status, the associations existed only among postmenopausal women (data not shown). However, when excluding patients with prior BP treatment, we did not observe any strong associations of bone biomarker levels with history of osteoporosis, any fracture, any major fracture, and age at first fracture, with the exception of RANKL levels being the highest and OPG/RANKL ratio being the lowest among those with any fracture more than 5 years before breast cancer diagnosis, compared to those with any fracture within 5 years or with no fracture history.
Discussion
In a large cohort of breast cancer patients, we found that bone metastasis, BP treatment and chemotherapy treatment had a strong impact on serum levels of bone remodeling biomarkers-TRAP5b and BAP-and bone regulating biomarkers-RANKL and OPG. In addition, age at Overall models adjusted for age at diagnosis (continuous, not for the analysis of age at diagnosis), menopausal status at baseline (Pre/Post, not for the analysis of menopausal status), and time of blood collection relative to chemotherapy (before/after) * p-values remain significant after correcting for a total of 120 tests (6 markers 9 20 variables, unadjusetd p \ 0.0004)
The BAP/TRAP5b ratio was log-transformed Breast Cancer Res Treat (2017) 161:501-513 507 diagnosis, self-reported race/ethnicity, body mass index, physical activity, alcohol intake, smoking, and hormone replacement therapy were also associated with the levels of these biomarkers. Nevertheless, there were few noteworthy relationships between these bone biomarkers with breast cancer clinical characteristics. BMD around breast cancer diagnosis was only weakly and negatively related with TRAP5b and BAP levels, but not with RANKL or OPG levels. Lastly, women with a recent history of osteoporosis or any fracture within 5 years of breast cancer diagnosis had lower levels of TRAP5b, BAP, and RANKL. Our finding of higher levels of bone remodeling biomarkers in patients with bone metastasis is expected. The growth of bone metastatic lesions causes increased bone resorption, and factors released from bone resorption stimulate cancer cell growth, forming a vicious cycle of bone destruction and elevated levels of degradation products in circulation [18] . Although RANKL has been hypothesized as a therapeutic target for bone metastasis [19] , our analyses in the small sample of bone metastatic patients in our study (n = 20) revealed no statistically significant difference in the serum levels of RANKL or OPG. These findings are consistent with most of the literature on using bone biomarkers for early diagnosis of bone metastasis [20] . Previous studies have shown that the levels of bone remodeling biomarkers, but not RANKL or OPG, were elevated in bone metastatic patients [21] [22] [23] ; however, the sensitivity and specificity for using these biomarkers to diagnose bone metastasis were limited [20] .
Few studies have characterized the associations of bone biomarkers with demographic, lifestyle, or clinical factors among women diagnosed with breast cancer. In our patient population, we found that older patients tend to have higher levels of bone resorption marker TRAP5b and lower BAP/ TRAP5b ratio, indicating a balance shifted toward bone resorption. However, they also had lower levels of RANKL and higher levels of OPG, and a higher OPG/RANKL ratio, indicating a balance favoring bone formation. This discordance was also reflected in the lack of correlation between RANKL/OPG and TRAP5b/BAP in our data. The higher levels of OPG in older patients were consistent with a study in postmenopausal women in the Women's Health Initiative (WHI), which did not find an association of RANKL levels with age [24] . Because BMD gradually declines after peaking in early adulthood [25] , the higher levels of TRAP5b and lower BAP/TRAP5b ratio found in our study better reflect this trend than RANKL or OPG levels and thus may be more appropriate biomarkers for the bone aging process.
High BMI as a measure of obesity was associated with lower levels of bone resorption biomarkers (TRAP5b and RANKL) and higher levels of bone formation biomarkers (BAP, OPG, BAP/TRAP5b, and OPG/RANKL). The associations may be explained by higher estrogen levels among women with high BMI, which are known to be critical in maintaining bone density in women [26] .
Alcohol consumption has been suggested to be protective for bone health among postmenopausal women, possibly by suppressing bone turnover [27, 28] . One earlier study showed that alcohol consumption was associated with reduced levels of both bone resorption and formation biomarkers [28] . In our study, we found lower levels of bone formation markers (BAP and OPG) among alcohol drinkers, particularly among postmenopausal women (data not shown), but no differences in bone resorption markers. Interestingly, in a rat animal model, bone formation was reduced in alcohol-fed animals [29] , consistent with our findings. The associations might be due to reduced parathyroid hormone or increased estrogen concentrations caused by alcohol consumption [27] .
Being physically active has, in general, been associated with higher BMD [30] . However, in our study, women with above median levels of physical activity had higher levels of TRAP5b and lower levels of OPG than those with no regular or below the median physical activity, thus indicating a balance shifted toward bone resorption. Published data on physical activity and bone biomarkers in adult women are sparse. The aforementioned WHI study did not find any association between energy expenditure from physical activity and RANKL or OPG levels [24] . Our findings may need validation in future studies among women with breast cancer. Overall models adjusted for age at diagnosis (continuous, not for the analysis of age at diagnosis), menopausal status at baseline (Pre/Post, not for the analysis of menopausal status), and time of blood collection relative to chemotherapy (before/after) * p-values remain significant after correcting for a total of 120 tests (6 markers 9 20 variables, unadjusetd p \ 0.0004)
The BAP/TRAP5b ratio was log-transformed Breast Cancer Res Treat (2017) 161:501-513 509 Interestingly, calcium or vitamin D supplementation had no impact on any biomarker levels measured in our study, in contrast to their well-established roles in bone metabolism. Although our analysis was observational, the null findings are consistent with those from several prospective trials of vitamin D and/or calcium supplementation [31] [32] [33] , which evaluated changes in bone remodeling biomarkers after intervention. The lack of an impact of supplementation on bone biomarkers might be due to the tight control of 1,25a-dihydroxyvitamin D levels, the active vitamin D metabolite in calcium homeostasis, which may be in a normal range even in individuals with vitamin D deficiency [34] . As a result, the impact of vitamin D or calcium supplementation may not be reflected in bone biomarkers.
The majority of breast cancers are estrogen receptor positive and/or progesterone receptor positive, making them eligible for hormonal therapy consisting of single or sequential use of tamoxifen or AIs. Because of superior efficacy compared with tamoxifen, AIs have largely replaced tamoxifen in the setting of postmenopausal breast cancer [35] . Nevertheless, AIs have a distinct profile of toxicities. Compared to osteo-protective effects of tamoxifen, the third-generation AIs can be damaging to bones by essentially cutting off estrogen synthesis from adipose tissues [36] . This significantly elevates the risk of osteoporosis and fragility fracture among postmenopausal women, who are already at high risk due to markedly lower estrogen levels after menopause. Several clinical trials reported a decrease in BMD and increase in bone turnover after AI treatment as measured by bone resorption and formation biomarkers [5] [6] [7] [8] . While these previous studies were focused on changes in bone remodeling biomarkers after AI treatment, to our knowledge, no studies have evaluated the predictive value of incorporating bone biomarker levels prior to treatment into a risk prediction model for AI-related fractures. We have now characterized in detail the associations of bone biomarkers measured before treatment with baseline patient characteristics, thus setting the stage for our future work to study these biomarkers with bone health outcomes after hormonal therapy.
In conclusion, in a large breast cancer survivor cohort, we found that serum levels of bone regulating and remodeling biomarkers at the time of breast cancer diagnosis were associated with several patient characteristics and lifestyle factors, but not with tumor characteristics, except for bone metastasis. We plan to investigate the association of these baseline biomarkers with the risk of osteoporosis and fracture after hormonal therapy in our future work.
